中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

4 records (took 0.01 seconds)

    Novel Anti-IL13 Antibodies and Uses Thereof
    2.
    发明申请
    Novel Anti-IL13 Antibodies and Uses Thereof 有权
    新型抗IL13​​抗体及其用途

    公开(公告)号：US20140105897A1

    公开(公告)日：2014-04-17

    申请号：US13971394

    申请日：2013-08-20

    Applicant: Genentech, Inc.

    Inventor： Sek Chung Fung ,  Matthew Moyle ,  Mason Lu ,  Changning Yan ,  Sanjaya Singh ,  Dan Huang

    IPC: C07K16/24

    CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/55522 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

    Abstract translation: 本发明涉及对糖基化和非糖基化的人IL13具有特异性和高亲和力结合的抗IL13​​抗体，不结合小鼠IL13，并以约2摩尔比（MAb：IL13）中和人IL13活性 ）。 本发明还涉及这些抗体在治疗IL13介导的疾病中的用途，所述疾病包括过敏性疾病，如过敏性疾病，包括哮喘，过敏性哮喘，非过敏性（内源性）哮喘，过敏性鼻炎，特应性皮炎，过敏性结膜炎，湿疹，荨麻疹 食物过敏，慢性阻塞性肺疾病，溃疡性结肠炎，RSV感染，葡萄膜炎，硬皮病和骨质疏松症。

    Anti-IL13 antibodies and uses thereof
    4.
    发明授权
    Anti-IL13 antibodies and uses thereof 有权

    公开(公告)号：US11434287B2

    公开(公告)日：2022-09-06

    申请号：US16682773

    申请日：2019-11-13

    Applicant: Genentech, Inc.

    Inventor： Sek Chung Fung ,  Matthew Moyle ,  Mason Lu ,  Changning Yan ,  Sanjaya Singh ,  Dan Huang

    IPC: A61K39/00 ,  C07K16/24

    Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Patent Agency Ranking